Why is it not recommended to take bosutinib?

Bosutinib (Bosutinib) is a drug that treats chronic myeloid leukemia (CML) and belongs to a class of drugs called tyrosine kinase inhibitors. Long-term results confirm that bosutinib is an effective and tolerable second-line therapy for patients with imatinib-resistant or imatinib-intolerant chronic-phase CML. While bosutinib can be effective in controlling the progression of leukemia in some cases, there are some potential risks and side effects associated with its use.

Bosutinib may cause a series of adverse reactions, including nausea, vomiting, diarrhea, rash, fatigue, etc. These side effects may affect the patient's quality of life and may require dose reduction or discontinuation of treatment in some cases. Bosutinib may interact with other drugs, especially other cancer drugs and certain heart drugs. This may result in higher or lower drug concentrations, affecting therapeutic efficacy or increasing the risk of adverse effects. Although bosutinib may be an option for the treatment of chronic myelogenous leukemia, its use requires physician guidance and monitoring due to its potential adverse effects and risks.

The originator drug of bosutinib is not marketed in the country, so it cannot be included in medical insurance. Currently, the original drugs sold overseas include Turkish version and European version. The price of the Turkish version may be more than RMB 2,000 per box of 500mg*28, and the price of the European version may be more than RMB 30,000 (the price may fluctuate due to the exchange rate). There are also bosutinib generic drugs produced overseas in other countries. Their pharmaceutical ingredients are basically the same as those of the original drug. The price of 500mg*30 per box may be more than 2,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.